You are here

A Four-Way Cross-Over Study To Compare The Plasma Concentrations Of PF-02413873 After Oral Administration Of Several Doses As Suspension And As Tablets.

Last updated on November 16, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Singapore, , 188770 Singapore
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Healthy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
21-55 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Healthy male and female volunteers.

- Female volunteers have to be of non-childbearing potential

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
allergic disease (including drug allergies, but excluding untreated, asymptomatic,
seasonal allergies at time of dosing).

- Any condition possibly affecting drug absorption (eg, gastrectomy).

- A positive urine drug screen.

NCT00857571
Pfizer
Terminated
A Four-Way Cross-Over Study To Compare The Plasma Concentrations Of PF-02413873 After Oral Administration Of Several Doses As Suspension And As Tablets.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Descriptive Information
Brief Title  ICMJE A Four-Way Cross-Over Study To Compare The Plasma Concentrations Of PF-02413873 After Oral Administration Of Several Doses As Suspension And As Tablets.
Official Title  ICMJE An Open-Label Randomized Incomplete Block Four-Way Crossover Study To Evaluate The Dose Response Of PF-02413873 Tablets And PF-02413873 Suspension.
Brief SummaryThe study compares the plasma concentrations of PF-02413873 after administration of several doses as suspension and as tablets
Detailed DescriptionNot Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Condition  ICMJE Healthy
Intervention  ICMJE
  • Drug: 150 mg Suspension
    Single oral dose of 150 mg of PF-02413873 suspension
  • Drug: 30 mg Suspension
    Single oral dose of 30 mg of PF-02413873 suspension
  • Drug: 400 mg Suspension
    Single oral dose of 400 mg of PF-02413873 suspension
  • Drug: 5 mg Suspension
    Single oral dose of 5 mg of PF-02413873 suspension
  • Drug: 750 mg Suspension
    Single oral dose of 750 mg of PF-02413873 suspension
  • Drug: 150 mg Tablet
    Single oral dose of 150 mg of PF-02413873 tablets
  • Drug: 30 mg Tablet
    Single oral dose of 30 mg of PF-02413873 tablets
  • Drug: 400 mg Tablet
    Single oral dose of 400 mg of PF-02413873 tablets
  • Drug: 5 mg Tablet
    Single oral dose of 5 mg of PF-02413873 tablets
  • Drug: 750 mg Tablet
    Single oral dose of 750 mg of PF-02413873 tablets
Study Arms  ICMJE
  • Experimental: Suspension
    PF-02413873 suspension
    Interventions:
    • Drug: 150 mg Suspension
    • Drug: 30 mg Suspension
    • Drug: 400 mg Suspension
    • Drug: 5 mg Suspension
    • Drug: 750 mg Suspension
  • Experimental: Tablet
    PF-02413873 Phase 2 Tablets
    Interventions:
    • Drug: 150 mg Tablet
    • Drug: 30 mg Tablet
    • Drug: 400 mg Tablet
    • Drug: 5 mg Tablet
    • Drug: 750 mg Tablet
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: December 5, 2018)
12
Original Estimated Enrollment  ICMJE
 (submitted: March 5, 2009)
30
Actual Study Completion Date  ICMJE May 2009
Actual Primary Completion DateMay 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Healthy male and female volunteers.
  • Female volunteers have to be of non-childbearing potential

Exclusion Criteria:

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
  • Any condition possibly affecting drug absorption (eg, gastrectomy).
  • A positive urine drug screen.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 21 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Singapore
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00857571
Other Study ID Numbers  ICMJE B0461003
Has Data Monitoring CommitteeNo
U.S. FDA-regulated ProductNot Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible PartyPfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateDecember 2018

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now